Krebs Biochemicals Financials
| KREBSBIO | 109.74 5.60 5.38% |
Operating Margin (0.30) | Profit Margin (0.37) |
Krebs | Select Account or Indicator |
Krebs Biochemicals Stock Summary
Krebs Biochemicals competes with Sapphire Foods, Agarwal Industrial, NRB Industrial, Sarthak Metals, and Ankit Metal. Krebs Biochemicals is entity of India. It is traded as Stock on NSE exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | India Stock View All |
| Exchange | National Stock Exchange of India |
| ISIN | INE268B01013 |
| Business Address | Kothapalli Village, Visakhapatnam, |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | krebsbiochem.com |
| Phone | 91 91 2114 4984 |
You should never invest in Krebs Biochemicals without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Krebs Stock, because this is throwing your money away. Analyzing the key information contained in Krebs Biochemicals' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Krebs Biochemicals Key Financial Ratios
Krebs Biochemicals' financial ratios allow both analysts and investors to convert raw data from Krebs Biochemicals' financial statements into concise, actionable information that can be used to evaluate the performance of Krebs Biochemicals over time and compare it to other companies across industries.| Revenue | 504.21 M | ||||
| Gross Profit | 244.19 M | ||||
| EBITDA | (82.73 M) | ||||
| Net Income | (197.28 M) | ||||
| Cash And Equivalents | (1 K) |
Krebs Biochemicals Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 1.3B | 1.6B | 1.9B | 1.7B | 1.8B | 1.3B | |
| Other Current Liab | 165.0M | 274.2M | 148.1M | 237.0M | 326.9M | 343.2M | |
| Net Debt | 811.6M | 998.4M | 580.7M | 1.8B | 2.4B | 2.5B | |
| Accounts Payable | 200.3M | 207.8M | 379.1M | 152.8M | 189.7M | 207.4M | |
| Cash | 560K | 7.1M | 324K | 858K | 1.4M | 1.3M | |
| Net Receivables | 2.8M | 3.0M | 19.5M | 6.5M | 47.3M | 66.4M | |
| Inventory | 150.0M | 166.0M | 255.6M | 119.5M | 102.4M | 145.7M | |
| Other Current Assets | 34.1M | 34.4M | 79.5M | 29.7M | 23.3M | 32.0M | |
| Total Liab | 1.6B | 2.0B | 2.6B | 2.7B | 3.0B | 1.8B | |
| Total Current Assets | 188.6M | 214.2M | 354.9M | 160.6M | 174.4M | 278.7M | |
| Common Stock | 166.3M | 180.0M | 196.2M | 215.6M | 247.9M | 154.5M | |
| Short Term Debt | 11.6M | 105.9M | 101.7M | 101.2M | 101.8M | 128.9M | |
| Retained Earnings | (1.5B) | (1.8B) | (2.3B) | (2.5B) | (2.7B) | (2.6B) | |
| Intangible Assets | 37.7M | 35.1M | 28.7M | 26.9M | 25.0M | 27.7M | |
| Other Liab | 515.7M | 501.6M | 532.1M | 539.0M | 619.9M | 439.3M | |
| Net Tangible Assets | (161.4M) | (268.4M) | (445.8M) | (769.4M) | (692.5M) | (657.8M) | |
| Other Assets | 73.8M | 96.0M | 82.5M | 27.1M | 24.4M | 23.2M | |
| Long Term Debt | 655.1M | 1.0B | 1.3B | 1.7B | 1.8B | 1.9B | |
| Short Long Term Debt | 7.1M | 105.9M | 99.9M | 99.9M | 99.3M | 113.0M | |
| Long Term Debt Total | 655.1M | 1.0B | 1.3B | 1.7B | 2.0B | 2.1B | |
| Cash And Equivalents | 4.2M | 147M | 0.0 | (1K) | (900.0) | (855.0) |
Krebs Biochemicals Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 60.0M | 62.8M | 54.4M | 29.7M | 46.9M | 41.6M | |
| Total Revenue | 235.8M | 386.1M | 529.4M | 521.3M | 504.2M | 274.5M | |
| Gross Profit | (93.3M) | (136.3M) | (207.6M) | 264.6M | (108.7M) | (103.3M) | |
| Operating Income | (240.3M) | (227.0M) | (402.9M) | (217.2M) | (152.0M) | (159.6M) | |
| Ebit | (227.5M) | (220.8M) | (391.4M) | (217.2M) | (150.4M) | (157.9M) | |
| Ebitda | (180.7M) | (169.6M) | (328.4M) | (151.6M) | (82.7M) | (86.9M) | |
| Cost Of Revenue | 329.1M | 522.3M | 737M | 256.8M | 613.0M | 342.2M | |
| Income Before Tax | (288.7M) | (283.6M) | (445.3M) | (246.9M) | (197.3M) | (207.1M) | |
| Net Income | (288.7M) | (283.6M) | (445.3M) | (246.9M) | (197.3M) | (207.1M) | |
| Income Tax Expense | 12.7M | 6.2M | 13.9M | 65.4M | 67.5M | 70.9M | |
| Interest Income | 51.5M | 62.8M | 3.6M | 29.7M | 34.2M | 40.7M | |
| Research Development | 9.7M | 14.7M | 16.4M | 11.3M | 12.7M | 11.1M | |
| Net Interest Income | (57.4M) | (62.8M) | (53.9M) | (29.7M) | (46.9M) | (49.2M) |
Krebs Biochemicals Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Krebs Biochemicals and. It measures of how well Krebs is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Krebs Biochemicals brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Krebs had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Krebs Biochemicals has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (60.3M) | (16.0M) | (89.6M) | 136.2M | 21.5M | 20.4M | |
| Change In Cash | (171.4M) | 5.4M | (6.1M) | (148K) | 516K | 490.2K | |
| Free Cash Flow | (452.7M) | (400.8M) | (407.4M) | (355.8M) | (50.2M) | (52.7M) | |
| Depreciation | 46.8M | 51.2M | 63.0M | 65.6M | 67.7M | 48.0M | |
| Other Non Cash Items | 55.6M | 65.5M | 51.2M | 32.6M | 51.2M | 53.7M | |
| Capital Expenditures | 94.1M | 255.1M | 235.2M | 108.7M | 94.2M | 91.7M | |
| Net Income | (288.7M) | (283.6M) | (445.3M) | (246.9M) | (197.3M) | (207.1M) | |
| End Period Cash Flow | 1.7M | 7.1M | 1.0M | 858K | 1.4M | 1.3M | |
| Net Borrowings | (12.6M) | 150.7M | 334.9M | 323.8M | 372.4M | 391.0M | |
| Change To Netincome | 58.0M | 42.7M | 65.5M | 51.1M | 58.8M | 61.8M |
Krebs Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Krebs Biochemicals's current stock value. Our valuation model uses many indicators to compare Krebs Biochemicals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Krebs Biochemicals competition to find correlations between indicators driving Krebs Biochemicals's intrinsic value. More Info.Krebs Biochemicals and is currently regarded as number one stock in return on asset category among its peers. It also is currently regarded as number one stock in profit margin category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Krebs Biochemicals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Krebs Biochemicals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Krebs Biochemicals and Systematic Risk
Krebs Biochemicals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Krebs Biochemicals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-eight with a total number of output elements of thirty-three. The Beta measures systematic risk based on how returns on Krebs Biochemicals and correlated with the market. If Beta is less than 0 Krebs Biochemicals generally moves in the opposite direction as compared to the market. If Krebs Biochemicals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Krebs Biochemicals and is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Krebs Biochemicals is generally in the same direction as the market. If Beta > 1 Krebs Biochemicals moves generally in the same direction as, but more than the movement of the benchmark.
Krebs Biochemicals and Common Stock Shares Outstanding Over Time
Krebs Biochemicals Thematic Clasifications
Krebs Biochemicals and is part of Chemicals Makers investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Chemicals for crops, soil, human, and animals. Companies developing chemicals for crops, soil as well as human, and animals
This theme covers Chemicals for crops, soil, human, and animals. Companies developing chemicals for crops, soil as well as human, and animals. Get More Thematic Ideas
| Chemicals Makers | View |
Krebs Biochemicals December 2, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Krebs Biochemicals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Krebs Biochemicals and. We use our internally-developed statistical techniques to arrive at the intrinsic value of Krebs Biochemicals and based on widely used predictive technical indicators. In general, we focus on analyzing Krebs Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Krebs Biochemicals's daily price indicators and compare them against related drivers.
| Downside Deviation | 2.82 | |||
| Information Ratio | 0.0665 | |||
| Maximum Drawdown | 29.86 | |||
| Value At Risk | (3.43) | |||
| Potential Upside | 5.0 |
Complementary Tools for Krebs Stock analysis
When running Krebs Biochemicals' price analysis, check to measure Krebs Biochemicals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krebs Biochemicals is operating at the current time. Most of Krebs Biochemicals' value examination focuses on studying past and present price action to predict the probability of Krebs Biochemicals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krebs Biochemicals' price. Additionally, you may evaluate how the addition of Krebs Biochemicals to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |